Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma

Zhong, Hua; Xu, Lan; Zhong, Jian‐Jiang; Xiao, Fei; Liu, Qiang; Huang, Honghui; Chen, Fangyuan

doi:10.3892/etm.2012.502

Cited by 54 publications

(59 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant expression of miR-146a was correlated with complete remission rate, higher overall response rate and longer progression-free survival time in patients with diffuse large B-cell lymphoma (Zhong et al 2012). In this study, the tissue levels of miR19b and miR-146a significantly influenced the OS in NSCLC patients with TNM stages I, II and III.…”

Section: Discussionmentioning

confidence: 69%

“…Overexpression of miR-146a can also inhibit NF-κB activity, thereby inhibiting proliferation and invasion of cancer cells as well as inducing apoptosis (Paik et al 2011;Li et al 2012a;Chen et al 2013a). However, miR-146a is upregulated in diffuse large B-cell lymphoma (Zhong et al 2012) and some invasive human breast cancer cell lines . Li et al (2012b) reported that miR-146a was highly expressed in brain metastasis in colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Cao

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

MicroRNA (miRNA) is a type of small non-coding RNA molecule that has important roles in cancer initiation, promotion and progression by negatively regulating gene expression. In this study, we explored the role of miRNAs in the prognosis of patients with non-small cell lung cancer (NSCLC). The miRNA expression profiles were determined in 5 pairs of NSCLC and paracancerous tissues (3 adenocarcinomas and 2 squamous cell carcinomas). Aberrantly expressed miRNAs were validated by quantitative real-time PCR (qRT-PCR) in 61 pairs of NSCLC and paracancerous tissues. Differentially expressed miRNAs were further analyzed in sera from 94 healthy subjects and 94 advanced NSCLC patients receiving platinumbased chemotherapy. Three miRNAs (miR-19b, miR-146a, and miR-223) were significantly dysregulated in NSCLC tissues (P < 0.05). High miR-19b and low miR-146a expression in NSCLC tissues were associated with higher TNM stage, lymph node metastasis and poorer survival (P < 0.05). The serum levels of miR-19b in NSCLC patients were significantly higher (P < 0.001), whereas serum levels of miR-146a were significantly lower (P < 0.001), compared with those in controls. Serum levels of miR-19b and miR-146a were associated with overall survival of NSCLC patients (P < 0.05). Patients with low serum level of miR-19b and high serum level of miR-146a achieved a higher overall response rate and longer survival time (P < 0.05). These data suggest that miR-19b and miR-146a are potential biomarkers for the prediction of survival and response to chemotherapy in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Cao

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Similarly, previous studies had elucidated an increased level of miR-155 expression in aggressive activated B-cell-like (ABC) subtype of DLBCL, primary mediastinal Bcell lymphoma (PMBL) and CLL. Their mean fold-change values had spanned from 3 to 19 in patients with DLBCL [29][30][31][32][33][34][35][36][37]. As well, a lot of studies have found down regulation of miR-155 expression levels within BL versus CLL, MCL and FL [38,39].…”

Section: Discussionmentioning

confidence: 99%

Expression Signature of MicroRNA-155 and its Association with Response to Treatment within Different Subtypes of B-Cell Malignancies

Eldin¹,

Naem²,

Higazi³

et al. 2017

Biol Med (Aligarh)

View full text Add to dashboard Cite

Objectives: Emerging evidence suggests that microRNAs could serve as non-invasive biomarkers for cancer patients. However, they are mostly not fully investigated as biomarkers in the classification, progression and prognosis of different cancers. Our study was designed to explore the microRNA-155 (miR-155) expression levels in peripheral blood mononuclear cells (PBMCs) in patients with various subtypes of B-cell malignancies. Also, we aimed to correlate between miR-155 expression levels and the diverse clinico-pathologic features as well as the prognostic fate of these patients after treatment completion. Subjects and methods:Using whole blood samples from 53 patients with B-cell malignancies and 15 apparently healthy subjects, miR-155 was extracted and profiled by quantitative real-time PCR (RT-qPCR). The B-cell malignancies patients were including 22 diffuse large B-cell lymphoma (DLBCL), 15 chronic lymphocytic leukemia (CLL), 9 follicular lymphoma patients (FL) and 7 subjects with burkitt′s lymphoma (BL). The samples were withdrawn before starting chemotherapy in addition to after completing their therapeutic courses by 6 months. Subsequently, the patients were further sub-grouped into those with partial remission, complete remission, resistant disease and relapse. Results:We found that miR-155 expression levels differentiate lymphoma entities from normal subjects (p ≤ 0.001) and its expression fold changes distinguish B-cell lymphoma subtypes from each other's (p<0.05). In addition, miR-155 was significantly correlated with age and LDH levels. The receiver operating curve (ROC) was employed to identify the diagnostic outcomes of miR-155 in discriminating B-cell malignancies entities from each other's (AUC=0.957 for DLBCL vs. CLL+FL and AUC=1.000 for CLL vs. FL). Otherwise, when BL was versus healthy controls the AUC was equal to 0.552. As well, we demonstrated an association between elevated miR-155 expression levels and poor response to treatment with increased cases of relapse, partial remission or resistance to treatment. Conclusions:This study suggests that miR-155 has an expression profile that differs according to B-cell malignancies subtype. Besides, miR-155 expression levels may modulate the patient's response to treatment. These results support a role for miR-155 to provide helpful diagnostic/prognostic information in B-cell malignancies and may highlight novel pathways to be targeted for therapeutics in the future.

show abstract

“…Studies have demonstrated that, compared with normal controls, miR-155 is significantly upregulated in DLBCL, and that its expression is significantly increased in patients with non-GCB-type versus GCB-type DLBCL (20). The central role of miR-155 in the pathogenesis and aggressiveness of DLBCL has been clearly defined (9): miR-155 directly downregulates V-Myc avian myelocytomatosis viral oncogene homolog (MYC) antagonists, including mitotic arrest deficient-like 1, MYC-associated factor X (MAX)-interacting protein 1, and MAX network transcriptional repressor.…”

Section: Functions and Targets Of Dysregulated Mirs In Dlbclmentioning

confidence: 99%

MicroRNAs in diffuse large B-cell lymphoma

Tong

Zou

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma

Cited by 54 publications

References 42 publications

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Expression Signature of MicroRNA-155 and its Association with Response to Treatment within Different Subtypes of B-Cell Malignancies

MicroRNAs in diffuse large B-cell lymphoma

Contact Info

Product

Resources

About